First encouraging price action/share trading day since release of positive FDA news. 2015 raised my hopes; now I'm willing to wait for 2016 to bring to fruition those hopes.
Rereading the last PRs and 8Ks there is a lot of good news and significant development.
Some 2015 highlights quick hits:
Hiring of 2 full time scientists in house in the ICHIMs (while Thomas is only a consultant now, Christine is still there and Landers on board as President also has scientific background.
Multiple presentations at national and international scientific meetings (a 1st for BMSN/RGBP)
The acquisition of pertinent T. Ichim's IP and the filing of several new patents expanding the overall IP.
Going from 2 INDs with delays to one approved IND and the other being collaborated on with outside help from well established Dr. in Kesari for dCellVax with opportunity for him to expand dCellVax IND into glioma or file an additional IND.
Concrete developments in the progress of NR2F6 with not only patented process for screening compounds, but now, after inhouse success in identifying candidates, they have JV with national government entity to confirm and refine those or additional compounds for possible cancer cures - THE POTENTIAL here goes far beyond HemaXellerate's.
Outsourcing to capable and known entities what they are not set up to do in house: CRL, NIH/NCATS, Cancer research institutes like the John Wayne Cancer Research Center and others.
Only downside I've had this year is the undervaluing of the company in selling convertible notes at discounts that are way too high and benefit a few insiders much more than any shareholder.
But overall, 2015 has indeed been a huge year of progress for a small company taking bigger steps and the fact that more and more outside scientists and entities are willing to collaborate and work with RGBP is a highly positive sign for the future.
GLTA. Hoping in 2016 I can pay off my mortgage and take my family on a nice vacation with RGBP.
